Compare · MGX vs RVMD
MGX vs RVMD
Side-by-side comparison of Metagenomi Therapeutics Inc. (MGX) and Revolution Medicines Inc. (RVMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MGX and RVMD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- RVMD is the larger of the two at $35.25B, about 786.8x MGX ($44.8M).
- Over the past year, MGX is down 15.8% and RVMD is up 314.0% - RVMD leads by 329.8 points.
- RVMD has been more active in the news (14 items in the past 4 weeks vs 7 for MGX).
- RVMD has more recent analyst coverage (25 ratings vs 8 for MGX).
- Company
- Metagenomi Therapeutics Inc.
- Revolution Medicines Inc.
- Price
- $1.20-0.83%
- $165.80+1.82%
- Market cap
- $44.8M
- $35.25B
- 1M return
- -7.69%
- +10.32%
- 1Y return
- -15.79%
- +313.98%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2024
- 2020
- News (4w)
- 7
- 14
- Recent ratings
- 8
- 25
Revolution Medicines Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.
Latest MGX
- SEC Form 4 filed by Director Reid Laurence
- SEC Form 4 filed by Director Dere Willard H
- SEC Form 4 filed by Director Bjerkholt Eric
- SEC Form 4 filed by Director Eckhardt Juergen
- Chief Financial Officer Wapnick Pamela sold $3,746 worth of shares (2,884 units at $1.30), decreasing direct ownership by 1% to 208,491 units (SEC Form 4) to satisfy withholding tax
- Officer Irish Jian sold $4,854 worth of shares (3,737 units at $1.30), decreasing direct ownership by 0.98% to 377,533 units (SEC Form 4) (for tax liability)
- Officer Wein Matthew sold $725 worth of shares (558 units at $1.30), decreasing direct ownership by 0.44% to 126,491 units (SEC Form 4) to satisfy withholding tax
- Metagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare Conference
- SEC Form 10-Q filed by Metagenomi Therapeutics Inc.
- Metagenomi Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
Latest RVMD
- SEC Form 8-K filed by Revolution Medicines Inc.
- Revolution Medicines Announces Planned Leadership Transition for Steve Kelsey, M.D.
- Officer Mancini Anthony sold $720,490 worth of shares (4,615 units at $156.12), decreasing direct ownership by 8% to 49,975 units (SEC Form 4) to satisfy withholding tax
- Officer Goldsmith Mark A sold $1,564,310 worth of shares (10,020 units at $156.12) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 267,330 units (SEC Form 4) to satisfy withholding tax
- General Counsel Cislini Jeff sold $336,749 worth of shares (2,157 units at $156.12) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 56,521 units (SEC Form 4) (for tax liability)
- Chief Financial Officer Anders Jack sold $424,956 worth of shares (2,722 units at $156.12) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 123,269 units (SEC Form 4) to satisfy withholding tax
- Officer Kelsey Stephen Michael sold $651,798 worth of shares (4,175 units at $156.12) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 291,876 units (SEC Form 4) (withholding tax)
- Chief Operating Officer Horn Margaret A exercised 90,000 shares at a strike of $30.82 and sold $14,972,110 worth of shares (93,575 units at $160.00) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 154,647 units (SEC Form 4) to cover taxes
- SEC Form 144 filed by Revolution Medicines Inc.
- SEC Form 144 filed by Revolution Medicines Inc.